Prezista is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. Prezista is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. Prezista must be co-administered with ritonavir (Prezista/ritonavir) and with other antiretroviral agents.
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program using the contact information at the bottom of this page.
- Information for Healthcare Professionals: Darunavir Ethalolate (marketed as Prezista)
- Dear Healthcare Professional letter regarding new prescribing information for Prezista (darunavir)